Item 7.01 Regulation FD Disclosure
On November 24, 2020, the Company announced the the authorization of the
Clinical Trial Application (CTA) in Spain for the initiation of a Phase 1, open
label, first-in-human clinical study of FS222. The press release is attached
hereto as Exhibit 99.1 and incorporated by reference herein. The information in
this paragraph (including Exhibit 99.1) shall not be deemed to be "filed" for
purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the
"Exchange Act"), or otherwise subject to the liabilities of that section, and is
not incorporated by reference into any filing under the Securities Act of 1933,
as amended, or the Securities Act.
--------------------------------------------------------------------------------
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit
Number Description
99.1 Press Release dated November 24, 2020.
104 Cover Page Interactive File (the cover page tags are embedded within the
Inline XBRL document)
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses